StockData
Lumexa Imaging Holdings, Inc. logo

Lumexa Imaging Holdings, Inc. (LMRI) company profile

LMRINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$14.63−0.16 (-1.08%)

Close on Nov 17, 2026Market cap $1.41BP/E –Yield –

About Lumexa Imaging

Services-Medical Laboratories, SIC 8071

Lumexa Imaging Holdings, Inc. provides diagnostic imaging services in the United States. The company offers a range of advanced and routine medical imaging modalities, including magnetic resonance imaging, computed tomography, positron emission tomography, x-rays, ultrasound, and mammography. It also operates Connexia, an internal teleradiology platform that transmits radiographic images to remote, subspecialized radiologists for clinical interpretation. Lumexa Imaging delivers these diagnostic procedures to patients who require screening and diagnostic evaluations, serving individuals referred by affiliated healthcare providers, independent medical practices, and health system partners.

The company is headquartered in Raleigh, North Carolina. Lumexa Imaging operates 188 outpatient imaging centers located across 13 U.S. states, including eight joint venture partnerships with regional health systems. Its clinical network is supported by approximately 350 employed radiologists alongside contracts with over 890 radiologists in independent medical groups, handling patient referrals across tens of thousands of physician practices nationwide.

Summary of the business section of Lumexa Imaging's latest annual report, written by StockData.

Company profile

Company

Legal name
Lumexa Imaging Holdings, Inc.
Founded
2018
Headquarters
Raleigh, NC
Address
4200 Six Forks Road, Suite 1000 27609
Phone
(704) 334-7830
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
LMRI
Exchange
Nasdaq
IPO date
Dec 12, 2025
Shares outstanding
96M, Aug 12, 2026
Filer category
<br>Emerging growth company
SEC CIK
2071288
CUSIP
550249106
ISIN
US5502491062
FIGI
BBG01YLK99T6
Share class FIGI
BBG01YLK9BQ4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Caitlin ZullaChief Executive Officer, Director129,728
James Edward Walker Jr.Principal Accounting Officer17,346
James Anthony MartinChief Financial Officer54,054
Russell StewartChief Medical Officer4,232
Julie SzekerChief Legal Officer & Corp Sec66,182
Bridget E. KarlinDirector19,358
Glenn A. EisenbergDirector19,358
Molly JosephDirector46,385
Henry Lee CooperDirector49,358
Robert Louis Mittl Jr.Director19,358
Brett BrodnaxDirector81,385
Matthew LungrenDirector19,358
Brian Thomas ReganDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Caitlin Zulla
Chief Executive Officer
$750.00K$3.50M$5.43M$9.02M$750.00K–$19.47M–
Tony Martin
Chief Financial Officer
$590.00K–$2.43M$4.21M$590.00K–$7.84M–
Julie Szeker
Former Chief Legal Officer and Corporate Secretary
$450.00K$1.75M$2.10M$663.47K–$15.51K$5.00M+703%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 12, 2025
Securities offered
25,000,000
Exchange
Nasdaq
First trading day
Dec 11, 2025
First-day close
$18.52
Lock-up ends (est.)
Jun 9, 2026

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?